metricas
covid
Annals of Hepatology Most often read
Journal Information

Most often read

33697
Updated recommendations for the management of metabolic dysfunction–associated steatotic liver disease (MASLD) by the Latin American working group
Luis Antonio Diaz, Juan Pablo Arab, Francisco Idalsoaga, Javiera Perelli, Javier Vega, Melisa Dirchwolf, Javiera Carreño, Bárbara Samith, ... Mario G. Pessoa
Ann Hepatol. 2025;30:101903
33697
Full text access
11933
Treatment for hepatocellular carcinoma after immunotherapy
Landon L. Chan, Tsz Tung Kwong, Johnny C.W. Yau, Stephen L. Chan
Ann Hepatol. 2025;30:101781
11933
Full text access
9966
Is the liver resilient to the process of ageing?
Nirupama Chatterjee, Rishabh Sharma, Pratibha R Kale, Nirupma Trehanpati, Gayatri Ramakrishna
Ann Hepatol. 2025;30:101580
9966
Full text access
7299
Soft drink consumption and increased risk of nonalcoholic fatty liver disease: Results from the health workers cohort study
Edgar Denova-Gutiérrez, Berenice Rivera-Paredez, Amado D. Quezada-Sánchez, Brianda I. Armenta-Guirado, Paloma Muñoz-Aguirre, Yvonne N. Flores, Rafael Velázquez-Cruz, Jorge Salmerón
Ann Hepatol. 2025;30:101566
7299
Full text access
6956
Chronic hepatitis B virus persistence: Mechanisms, consequences and implications for achieving cure
Christopher Georgi, Simmone D’Souza, Carla Osiowy, Carla S. Coffin, Curtis L. Cooper
Ann Hepatol. 2025;30:101938
6956
Full text access
5785
Global burden and future trends of metabolic dysfunction-associated Steatotic liver disease: 1990-2021 to 2045
Chengxia Kan, Kexin Zhang, Yuqun Wang, Xiaofei Zhang, Chang Liu, Yanhui Ma, Ningning Hou, Na Huang, ... Xiaodong Sun
Ann Hepatol. 2025;30:101898
5785
Full text access
5494
A comprehensive meta-analysis of stem cell therapy for liver failure: Assessing treatment efficacy and modality
Shenglong Lin, Haibing Gao, Huaxi Ma, Ziyuan Liao, Dongqing Zhang, Jinshui Pan, Yueyong Zhu
Ann Hepatol. 2025;30:101586
5494
Full text access
5436
Diagnostic performance of FibroTouch® in assessing hepatic steatosis and fibrosis in patients with metabolic dysfunction-associated steatotic liver disease: An Asian experience
Thanikan Sukaram, Soe Thiha Maung, Yuda Chongpison, Tassanan Jaihan, Chonlada Phathong, Roongruedee Chaiteerakij
Ann Hepatol. 2025;30:101753
5436
Full text access
5386
Association of sleep patterns and disorders with metabolic dysfunction-associated steatotic liver disease and liver fibrosis in contemporary American adults
Guannan Zong, Wangjia Mao, Ming Wen, Xiaoyun Cheng, Guanghui Liu
Ann Hepatol. 2025;30:101583
5386
Full text access
5177
Mechanisms and therapeutic targets of mitochondria in the progression of metabolic dysfunction-associated steatotic liver disease
Chenyang Mu, Sijie Wang, Zenghan Wang, Jian Tan, Haozan Yin, Yuefan Wang, Zhihui Dai, Dongyang Ding, Fu Yang
Ann Hepatol. 2025;30:101774
5177
Full text access
4977
cccDNA epigenetic regulator as target for therapeutical vaccine development against hepatitis B
Patricia Gita Naully, Marselina Irasonia Tan, Agustiningsih Agustiningsih, Caecilia Sukowati, Ernawati Arifin Giri-Rachman
Ann Hepatol. 2025;30:101533
4977
Full text access
4741
From gut to liver: Exploring the crosstalk between gut-liver axis and oxidative stress in metabolic dysfunction-associated steatotic liver disease
Mi Zhou, Jianyu Lv, Xinli Chen, Yujie Shi, Guanqun Chao, Shuo Zhang
Ann Hepatol. 2025;30:101777
4741
Full text access
4713
A global comparison of hepatitis B & C drug pricing
Leah Yao, Xiaohan Ying, Getan Malik, Catherine Tsai, Arun B. Jesudian, Robert S. Brown Jr., Stephen E. Congly
Ann Hepatol. 2025;30:101928
4713
Full text access
4229
Latin American association for the study of the liver (ALEH) guidance on preoperative care in liver transplantation: referral criteria, patient assessment, and waiting list management
Victoria Mainardi, Josefina Pages, Josemaría Menendez, Rodrigo Zapata, Luis Antonio Díaz, Sebastian Marciano, Fernando Cairo, Martin Padilla-Machaca, ... Alejandra Villamil
Ann Hepatol. 2025;30:101939
4229
Full text access
4158
Brain reserve in hepatic encephalopathy: Pathways of damage and preventive strategies through lifestyle and therapeutic interventions
Jacqueline Cordova-Gallardo, Andres Manuel Vargas-Beltran, Samantha Melanie Armendariz-Pineda, Jesus Ruiz-Manriquez, Javier Ampuero, Aldo Torre
Ann Hepatol. 2025;30:101740
4158
Full text access
4145
The burden of hepatic encephalopathy and the use of albumin as a potential treatment
Jasmohan S. Bajaj, Enrico Pompili, Paolo Caraceni
Ann Hepatol. 2025;30:101751
4145
Full text access
3600
A landscape of liver cirrhosis and transplantation in Mexico: Changing leading causes and transplant as response
Icela Palma-Lara, María Guadalupe Ortiz-López, José Bonilla-Delgado, Juanita Pérez-Escobar, Ricardo Godínez-Aguilar, Claudia Luévano-Contreras, Ana María Espinosa-García, Javier Pérez-Durán, ... Carmen Palacios-Reyes
Ann Hepatol. 2025;30:101562
3600
Full text access
3569
Latin American association for the study of the liver (ALEH) guidance on postoperative care after liver transplantation
Liana Codes, Rodrigo Zapata, Manuel Mendizabal, Alfeu de Medeiros Fleck Junior, Juan Carlos Restrepo, Leonardo de Lucca Schiavon, Luiz Marcelo Sá Malbouisson, Wellington Andraus, ... members of ALEH Special Interest Group on Liver Transplantation
Ann Hepatol. 2025;30:101899
3569
Full text access
3477
Rifaximin treatment in patients with severe alcohol-associated hepatitis: A multicenter, randomized controlled, open-label, pilot trial
Do Seon Song, Jin Mo Yang, Young Kul Jung, Hyung Joon Yim, Hee Yeon Kim, Chang Wook Kim, Soon Sun Kim, Jae Youn Cheong, ... Young Seok Kim
Ann Hepatol. 2025;30:101749
3477
Full text access
Article options
Tools